References Home page

title

content

DISEASES A

Cancer

1. Blagosklonny MV. Rapalogs in cancer prevention, Anti-aging or anticancer? Cancer Biol Ther. 2012;13(14): 1349-1354.


2. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Bol Ther. 2008; 7:10, 1520-1524.


3. Blagosklonny MV. NCI's provocative questions oncancer: some answers to ignite discussion. Oncotarget 2011; 2(12) 135-1367.

Mouse Studies, normal mice

4. Harrison DE. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460:392-395.


5. Miller RA. Rapamycin, But Not Resveratrol or Simvastatin, Extends LifeSpan of Genetically Heterogeneous Mice. J Gerontol A Biol Sci Med Sci. 2011 66A(2): 191-201.


6. Miller RA. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014: 13(3): 468-477.


7. Anisimov VN. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10:24, 4230-4236. 

Mouse Studies, Cancer prone

8. Anisimov VN. Rapamycin Extends Lifespan in Cancer-Prone Mice. Am J Pathol. 2010. 176(5): 2092-2097.


9. Popovich IG. Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. Cancer Biol Ther. 2014. 15(5) 586-592. 


10. Komarova EA. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging. 2012. 4(10:709-714.


11. Comas M. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice be delaying carcinogenesis. Aging. 2012. 4(10):  715-722.


12. Donehower L. Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency. Aging. 2012.4(10): 660-661. 

P

R

S

H

d

C

NAFLD

1. Baffy, G. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. J Clin. Transl Hepatol. 2013: 1(2): 131-137.


2. Sapp V. Fructose Leads to Hepatic Steatosis in Zebrafish that is Reversed by Mechanistic Target of Rapamycin (mTOR) Inhibition.  Hepatology. 2014;  60: 1581-1592. 


3. Gabele E. Rapamycin decreases proinflammatory and profibrogenic gene expression in experimental NASH. Gastroenterologie. 2018; 108.30.152.37.


4. Lin C. Pharmacological Promotion of Autophagy Alleviates Steatosis and Injury in Alcoholic and Non-alcoholic Fatty Liver Consitions in Mice. J Hepatol. 2013; 58(5): 993-999. 


5. Zatloukal K. From Mallory to Mallory-Denk bodies: what, how and why ?. Exp Cell Res.2007; 313(10): 2033-49. 


6. Kucukoglu O. High-fat diet triggers Mallory-Denk body formation through misfolding and crosslinking of excess keratin 8. Hepatology. 2014; 60:1-20.


7. Harada M. Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation. Hepatology. 2008; 47(6): 2026-35.


8. Kubrusly M. A role for mammalian target of rapamycin (mTOR) pathway in non alcoholic steatohepatitis related-cirrhosis. Histology and Histopathology. 2010. 25: 1123-1131. 


9. Wang Y. Mammalian target of the rapamycin pathway is involved in non-alcoholic fatty liver disease. Mol Med Rep. 2010. 3(6):909-15.


10. Wang X. Ezetimibe alleviates non-alcoholic fatty liver disease through the miR-16 inhibiting mTOR/p70S6K1 pathway. Royal Society of Chemistry. 2017. 7, 37967-37974.


11. Lavallard V. Autophagy and Non-Alcoholic Fatty Liver Disease. Biomed Res Int. 2014. 10.1155; 1-21.


12. Yang L. Defective Hepatic Autophagy in Obesity Promotes ER Stress and Causes Insulin Resistance. Cell Metab. 2010. 11(6): 467-478.


13. Singh R. Autophagy regulates lipid metabolism. Nature. 2009. 30: 458(: 1131-1135.

Disease B

BPH

c

Osteoporosis

c

Age-related Macular Degeneration

1. Zheng S. Chemoprevention of age-related macular degeneration (AMD) with rapamycin. Aging. 2012; 4(6) 375-376.


2. Kolosova NG, Blagosklonny MV. Prevention of Age-Related Macular Degeneration-Like Retinopathy by Rapamycin in Rats. Am J Pathol. 2012;181(2):472-7.

C

c

C

c

C

C